Oragenics – pharmaceutical daily

May 20, 2019 Off

Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis

Phase 2 Clinical Trial Enrollment Progresses While World Health Organization Provides Generic Name of AG013 Compound TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc.…

March 21, 2019 Off

Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering

By BusinessWire

TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective…

March 15, 2019 Off

Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial

By BusinessWire

TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective…